Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
| Market Cap | 217.09M-19.1% |
| Revenue (ttm) | 229.28M+8.1% |
| Net Income | -274.83M-226.4% |
| EPS | -4.62-224.3% |
| Shares Out | 60.47M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,239,107 |
| Open | 3.84 |
| Previous Close | 3.88 |
| Day's Range | 3.56 - 3.88 |
| 52-Week Range | 3.56 - 9.94 |
| Beta | 0.73 |
| Analysts | Buy |
| Price Target | 15.50(+331.75%) |
| Earnings Date | Feb 10, 2027 |
3 qualifying trades · 1 insider · $38.09K bought in the last 90 days
Vanda Pharmaceuticals Inc. Stock Analysis — InsiderScore
See top-rated InsiderScore stocks ›Vanda Pharmaceuticals Inc. scored higher than 89% of companies evaluated by InsiderBuying, and ranked 9th out of 97 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Vanda Pharmaceuticals Inc. bought $38.1K of stock across 3 purchases in the last 90 days, the largest of them $22.1K.
The average purchase added about 3% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
Every buyer already held stock, so each purchase is an increase rather than a first position.
This category carries 35% of the Insider Score.
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
2 firms rating VNDA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 10, 2027Earnings report
Ask Barron about VNDA
$VNDA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VNDA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VNDA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VNDA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VNDA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VNDA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VNDA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $8.65M |
| XBIState Street SPDR S&P Biotech ETF | $7.27M |
| IWMiShares Russell 2000 ETF | $5.48M |
| VXFVanguard Extended Market ETF | $3.52M |
| IWNiShares Russell 2000 Value ETF | $2.01M |
| DFASDimensional - US Small Cap ETF | $1.78M |
Estimated from each fund’s disclosed top holdings × AUM
VNDA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VNDA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: ranks #9 of 97 scored Biotech stocks · sector average 59.5
What’s Behind the Score
News check: Positive Phase III trial results for lead drug HETLIOZ met primary endpoints, though stock reaction was muted post-announcement.